A Meta-Analysis Comparing Open-Label versus Placebo- Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises

키워드

참고문헌 (41)

1. Egede LE, "Major depression in individuals with chronic medical disorders:prevalence, correlates and association with health resource utilization, lost productivity and functional disability", Gen Hosp Psychiatry, 29, pp.409~416 (2007)
2. Kessler RC, "The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)", JAMA, 289, pp.3095~3105 (2003)
3. "Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association", Am J Psychiatry, 157(4 Suppl), pp.1~45 (2000)
4. Thase ME, "Are SNRIs more effective than SSRIs? A review of the current state of the controversy", Psychopharmacol Bull, 41, pp.58~85 (2008)
5. Papakostas GI, "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents", Biol Psychiatry, 62, pp.1217~1227 (2007)
6. Cipriani A, "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis", Lancet, 373, pp.746~758 (2009)
7. Fava M, "Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study", Psychiatr Clin North Am, 26, pp.457~494 (2003)
8. Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
9. Nierenberg AA, "Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report", Psychol Med, 40, pp.41~50 (2010)
10. Paykel ES, "Residual symptoms after partial remission: an important outcome in depression", Psychol Med, 25, pp.1171~1180 (1995)
11. Thase ME, "Evaluating antidepressant therapies: remission as the optimal outcome", J Clin Psychiatry, 64(Suppl 13), pp.18~25 (2003)
12. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder", World J Biol Psychiatry, 3, pp.5~43 (2002)
13. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
14. Kennedy SH, "Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments", Can J Psychiatry, 46(Suppl 1), pp.38S~58S (2001)
15. Philip NS, "Augmentation of antidepressants with atypical antipsychotics: a review of the current literature", J Psychiatr Pract, 14, pp.34~44 (2008)
16. Muller MJ, "Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale", J Affect Disord, 600, pp.137~140 (2000)
17. Baker WL, "Understanding heterogeneity in meta-analysis: the role of meta-regression", Int J Clin Pract, 63, pp.1426~1434 (2009)
18. Chen SJ, "The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial", J Clin Psychopharmacol, 32, pp.56~60 (2012)
19. Fabrazzo M, "Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study", Eur Neuropsychopharmacol, 22, pp.132~136 (2012)
20. Sheffrin M, "Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission", J Clin Psychiatry, 70, pp.208~213 (2009)
21. Matthews JD, "An open study of aripiprazole and escitalopram for psychotic major depressive disorder", J Clin Psychopharmacol, 29, pp.73~76 (2009)
22. Hellerstein DJ, "Aripiprazole as an adjunctive treatment for refractory unipolar depression", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.744~750 (2008)
23. Schule C, "Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study", World J Biol Psychiatry, 8, pp.112~122 (2007)
24. Rutherford B, "An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression", Int J Geriatr Psychiatry, 22, pp.986~991 (2007)
25. Patkar AA, "An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression", Prim Care Companion J Clin Psychiatry, 8, pp.82~87 (2006)
26. Papakostas GI, "Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder", J Clin Psychiatry, 66, pp.1326~1330 (2005)
27. Simon JS, "Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder", J Clin Psychiatry, 66, pp.1216~1220 (2005)
28. Nierenberg AA, "Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder", Australian and New Zealand Journal of Psychiatry, 43, pp.956~967 (2009)
29. Pae CU, "Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: A 12-week prospective open-label multicentre study", International Clinical Psychopharmacology 28(6), 28(6), pp.322~329 (2013), Lippincott Williams and Wilkins
30. Pae CU, "Aripiprazole augmentation for treatment of patients with inadequate antidepressants response", DEPRESSION AND ANXIETY, 24, pp.522~526 (2007), WILEY-LISS
31. Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
32. Berman RM, "Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants", CNS Spectr, 14, pp.197~206 (2009)
33. Marcus RN, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychopharmacol, 28, pp.156~165 (2008)
34. Fava M, "A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)", Psychother Psychosom, 81, pp.87~97 (2012)
35. Lin CH, "Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study", J Clin Psychopharmacol, 31, pp.563~568 (2011)
36. Mischoulon D, "Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial", J Clin Psychiatry, 73, pp.353~357 (2012)
37. "9.7 Sensitivity analyses In Cochrane Handbook for Systematic Reviews of Interventions"[URL]
38. Biederman J, "How informative are open-label studies for youth with bipolar disorder? A meta-analysis comparing open-label versus randomized, placebo-controlled clinical trials", J Clin Psychiatry, 73, pp.358~365 (2012)
39. Iovieno N, "Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis", J Clin Psychiatry, 73, pp.1300~1306 (2012)
40. Iovieno N, "Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation", combination strategies in treatment partial responders, J Clin Psychiatry, pp.2012, 73[DOI]
41. David M. Marks, "Innovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches", PSYCHIATRY INVESTIGATION, 6(1), pp.1~6 (2009), 대한신경정신의학회

관련 논문AI추천